Biochemical Effects and Toxicity of Mitoxantrone in Cultured Heart Cells

  • N. G. Shipp
  • R. T. Dorr
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 283)


In response to the cumulative cardiotoxicity associated with the clinical use of the antitumor agent doxorubicin, many structurally related anthraquinone drugs have been developed. Mitoxantrone has been the most successful of these, and is used with increasing frequency in the treatment of leukemia, lymphoma, and breast cancer. Response rates are similar to those obtained with doxorubicin treatment, and notably, mitoxantrone is less cardiotoxic. However, while more courses of mitoxantrone therapy can be given, patients eventually develop a cumulative cardiotoxicity which is clinically similar to that observed following prolonged doxorubicin treatment (Henderson et al., 1989).


Covalent Binding Heart Cell Malondialdehyde Level Culture Heart Cell Mitoxantrone Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dorr, R. T., Bozak, K. A., Shipp, N. G., Hendrix, M., Alberts, D. S., and Ahmann, F. (1988). In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphatel protein ratios. Cancer Research 48, 5222–5227.PubMedGoogle Scholar
  2. Henderson, I. C., Allegra, J. C., Woodcock, T., Wolff, S., Bryan, S., Cartwright, K., Dukart, G., and Henry, D. (1989). Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7, 560–571.PubMedGoogle Scholar
  3. Herman, E. H., and Ferrans, V. J. (1987). Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat. Rev. 14, 225–229.CrossRefPubMedGoogle Scholar
  4. Kharasch E. D., and Novak, R. F. (1985). Mitoxantrone and ametantrone inhibit hydroperoxide-dependent initiation and propagation reactions in fatty acid peroxidation. J. Biol. Chem. 260, 10645–10652.PubMedGoogle Scholar
  5. Reszka, K., Hartley, J. A., Kolodziejczyk, P., and Lown, J. W. (1989). Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids. Biochem. Pharm. 38, 4253–4260.CrossRefPubMedGoogle Scholar
  6. Stacy, N. H., Cantilena, L. R., and Klaassen, C. D. (1980). Cadmium toxicity and lipid peroxidation in sisolated hepatocytes. Toxicol. Appi. Pharmacol. 53, 470–480.CrossRefGoogle Scholar
  7. Wallin, H., Schelin, C., Tunek, A., and Jergil, B. (1981). A rapid and sensitive method for determination of covalent binding of benzo(a)pyrene to proteins. Chem.-Biol. Interactions. 38, 109–118.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • N. G. Shipp
    • 1
  • R. T. Dorr
    • 1
  1. 1.Dept. of Pharmacology and Toxicology and The Arizona Cancer CenterUniversity of ArizonaTucsonUSA

Personalised recommendations